CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

COVID-19 treatmentWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D014777 Virus Diseases NIH 0.12

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Evaluation of Immune Response in COVID-19 Patients

The aim of the project is to evaluate the immunological features of COVID-19 patients. Patients are recruited without any pharmacological treatments restriction. The number of samples is estimated on the basis of feasibility, that means on the maximum number of patients with COVID-19, who are expected to be able to be enrolled by the units involved. Based on the investigators' experience, gained in the onco-immunological field, considering the time and economic resources available, the investigators expect to enroll at least 80 patients.

NCT04438629 Allergy and Immunology Infection Viral Drug: COVID-19 treatment
MeSH:Virus Diseases

Primary Outcomes

Description: Enumeration of circulating cell subsets by flow cytometry [Cell count/µl]

Measure: COVID-19 associated immune disorder

Time: 24 hours

Description: Quantification of plasma levels of different solubles factors (GM-CSF, G-CSF, M-CSF, IFN-γ, IFN-α, IL-1, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17A, IL-17F, IL-17E, IL-21, IL-22, IL-23, IL-27, IL-28A, IL-31, IL-33, IL-34, MIP-3α/CCL20, CCL2, TNF-α, TNF-β, TGFβ) [pg/ml]

Measure: COVID-19 associated inflammation

Time: 48 hours

Description: Ratio of arterial oxygen tension (mmHg) to fraction of inspired oxygen (PaO2/FiO2)

Measure: Oxygenation

Time: 24 hours

Description: SARS-CoV-2 infection will be tested by PCR using nasopharyngeal swab

Measure: Diagnostic of COVID disease composite

Time: On admission of hospital

Secondary Outcomes

Description: Quantification of plasma levels of different solubles factors (GM-CSF, G-CSF, M-CSF, IFN-γ, IFN-α, IL-1, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17A, IL-17F, IL-17E, IL-21, IL-22, IL-23, IL-27, IL-28A, IL-31, IL-33, IL-34, MIP-3α/CCL20, CCL2, TNF-α, TNF-β, TGFβ) [pg/ml]

Measure: Changes at the cytokine pattern

Time: 14 Days

Description: Enumeration of circulating cell subsets by flow cytometry [Cell count/µl]

Measure: Changes at circulating immune cell composition

Time: 14 Days

Description: Proportion of patients with Intensive Care Unit Admission requirement

Measure: Intensive Care Unit Admission

Time: Day 7-14

Description: Days of Hospitalization

Measure: Length of hospital stay

Time: Day 7-14

Description: Clinical status assessed according to the World Health Organization guideline

Measure: Clinical Status

Time: Day 7-14

Description: Proportion of death patients at days

Measure: Mortality

Time: Day 7-14

No related HPO nodes (Using clinical trials)